

Office Address: Phone: +40-256-495403  
C. Porumbescu, Str. Nr. 59. +40-745-148485 (mobil)  
Timisoara, 300239, Romania Fax: +40-256-201041  
E-mail: coprean@yahoo.com

# Cristina Marinela Oprean, MD

---

**Personal dates** Professional registration number: 869035

**Education/** -2024.- ESO& Ulm. University Certificate of Competence in Breast Cancer  
**Board** -2011- **Specialist Clinical Pharmacology.Medicine University Timisoara**  
**Certification** -2008-**Senior Specialist in Medical Oncology License - Cluj, Romania**  
**s** -2006-**MBA.Certificate- British Academy of Business,Comunication**  
-2003-**Specialist in Medical Oncology License - Bucharest. Romania**  
-2001-**General abdominal ultrasound competence - Timisoara. Romania**  
-1999-**Specilalist General Practitioner License - Timisoara. Romania**  
-1989-1995.**M.D- Medical Doctor License-University of Medicine Timisoara**  
-1985-1989.**High School Diploma- High School for Nurse Timisoara**

**Postgraduate courses /trainings** - 2022-2024 - European School of Oncology Postgraduate Program-  
**Certificate of Competence in Breast Cancer Course**  
-2011.8-9.April. European School of Oncology Course. Viareggio. Italy  
**"Gene Profiling in Clinical Oncology"**  
-2011.April.1. European School of Oncology Course . Stresa. Italy  
**"Rare Solid Cancers-an Introduction"**  
-2010.December. 5-7.Dermatology Department . University of Kiel  
Germany -19<sup>th</sup> Melanoma Perceptorship Meeting  
**"Sentinel Node Biopsy and adjuvant Treatment"**  
-2010-May.01-31 EUSOMA-ESO-ESSO-Training Project. Oncology  
Department Frauenkliniken der Ludwig-Maximilians University Munich.  
**"The Multidisciplinary Approach on Breast Cancer Care"**  
-2009.June.11-12 European School of Oncology Course. Dublin. Ireland  
**"Evidence Based Oncology"**  
-2009.May.6-7.IMPACT Breast Cancer Conference. Brussels. Belgium  
**" Pre-IMPACT Training Course "- Susan.G.Komen for the cure Grant**  
-2009.March21-26 European School of Oncology Course.Sintra.Portugal  
**"8<sup>th</sup> Masterclass in Clinical Oncology "** –participation with ESO Grant  
-2008.October.30-3<sup>rd</sup> Annual Multidisciplinary Symposium. Paris. France  
**" Improving Clinical Outcomes in Genitourinary Malignancy"**  
-2008.April.03-04. 3<sup>rd</sup> Central European Course. Vienna. Austria  
**"Methodology of Clinical Trials in Oncology"**  
-2007.November.17.PRIME Oncology Course. Athens.Grece  
**"Expert Practice in Breast Cancer"**  
-2007.November.24.PRIME Oncology Course .Nice.France.  
**"Expert Practice in Lung Cancer"**  
-2006.November.18.ONE Course. Berlin, Germany  
**"Challenging Cases in Breast Cancer"**  
-2006.October.6-7.ONE Course.MonteCarlo.Monaco  
**"Improving Clinical Outcomes in Genitourinary Malignancy"**  
-2006.September.7-9.ESO Course. Stockholm. Sweden  
**"Palliative Cancer Care"**  
-2006.May.12-13.ESO Advanced Course. Belgrade. Serbia

**“Evidence Based Management of Lung Cancer”**

-2005.June.25.CESAR Course.Vienna.Austria

**“State of art in treatment of breast cancer”**

-2005.May.28-30.ESO Advanced Course. Milocer. Republic Muntenegro

**“Advances in Clinical Oncology”**

-2005.April.13-15.ESMO.Translational Research Visit. Barcelona. Spain

**“Early Clinical Development of Molecular Target Therapies”**

-2004.June.17-19: ESMO Advance Course .Rhodes. Greece

**“New Perspectives: Chest Tumors Integration of Research ”**

-2004.Mar.6-11European School of Oncology Course.Limassol.Cyprus

**“Masterclass in Clinical Oncology”**, participation with an ESO Grant

-2003.September.4-6: ESMO Course Warsaw. Poland

**“Principles and practices in Medical Oncology”**

-2003.August. 18-21: Vienna School of Clinical Research.Vienna.Austria

**“Publication workshop”** -participation with a VSCR Grant

-2003.June.21-27: 5<sup>th</sup> FECS/AACR/ASCO Workshop .Flims.Switzerland.

**“Methods in Clinical Research”**

-2003.May. 26-28. Vienna School of Clinical Research . -Vienna. Austria

**“Advanced Good Clinical Practice for experts in clinical research”**

**Professional  
qualifications  
and  
experience**

**Current positions:**

- **Reviewer** for papers in oncology field in international medical journals- since 2021 January
- **Chef of Oncology Day Hospital. Oncohelp.Timisoara.Romania**-since May 2015 -present
- Specialist in Clinical Pharmacology Consultant** Oncohelp Hospital Timisoara- since 2011
- Scientific advisor - oncology field for Pharma Industry** –since 2010
- Senior Specialist in Medical Oncology**- since October 2009- Oncohelp Hospital – Timisoara. Romania
- **Senior Specialist in Medical Oncology**- since December 2008. Oncomed Outpatient Unit - Timisoara. Romania.
- **Principal Investigator in Clinical Trials in Oncology**- since December 2008 in 70 clinical studies phase II, III and IV in colon, pancreatic, lung, gastric, malign melanoma, breast, prostate, ovarian, head and neck cancer and supportive cancer care
- **Subinvestigator in clinical trials in oncology** since 2001- in 100 clinical studies in lung, breast, ovarian, colon, gastric, prostate ,malign melanoma, pancreatic cancer and supportive care

**Past positions:**

- Chef of Oncology Compartment**; Senior Specialist Consultant in Medical Oncology Military Hospital Timisoara April 2012- April 2015
- **Chef of Oncology Department** Oncohelp Hospital. Timisoara. Romania 1<sup>st</sup> July 2011- 1<sup>st</sup> April 2012
- **Specialist in Medical Oncology**- 2004-2008. Oncomed. Timisoara
- **Resident in Medical Oncology**-1999- 2004. City Hospital. Oncology Department. Timisoara. Romania.
- Study coordinator in clinical trials** - 2004 - 2008 in 30 clinical studies phase II,III,IV in the same indication in oncology
- Resident in General Medicine (Family Doctor)**-1999-1996. County Hospital. Family Medicine Department . Timisoara. Romania
- Nurse** in Internal Medicine -1993 -1995 part time . County Hospital. Internal Medicine Department. Timisoara. Romania

**Publications  
list**

1. "Real World, National Study of Palbociclib in HR+/HER2-Metastatic Breast Cancer: A 2,5 Years Follow-Up" **PALBO01/2021**" *Diagnostics*.05.May.2025. DOI 10.3390/15091173.
2. "Risk factors for cancer recurrence in postmenopausal women: a bibliometric study". *Frontiers in Oncology* .Vol 15. 01.April.2025.DOI.10.3389/fonc.2025.1522713
3. "Perception of disease, dyadic coping, and the quality of life of oncology patients in the active treatment phase and their life partners: an approach based on the actor-partner interdependence model", *Front. Psychol.*14.Apr.2024.DOI:10.3389/fpsyg.2023.1069767
4. "Interim Analysis Results from a European Registry Study Aimed to Prospectively observed Patterns and Outcomes in Patients with Her2+ Unresectable Locally Advanced or Metastatic Breast Cancer" *Cancer Research*.2023.March.01.DOI 10.1158/1538-7445.SABCS22-P3-02-05
5. "Pregnancy in a Young Patient with Metastatic HER2-Positive Breast Cancer-Between Fear of Recurrence and Desire to Procreate", *Current Oncology*.08.May.2023.30,4833–4843. DOI:10.3390/currenol30050364
6. "Attitudes towards COVID-19 vaccination in patients with cancer: A cross-sectional study of 12 oncology centers", *Molecular and Clinical Oncology*2022.17.122.September.23.2022.DOI/10.3892/mco.2022.2595
7. "Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients" *Int. J. Environ. Res. Public Health* 2022, 19,4314. April.04.2022./DOI:10.3390/ijerph19074314
8. "Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis-The Adjuvant Role of Lifestyle Changes" *Curr. Oncol.* 2022, 29, 1890–1901.March.10.2022. DOI: 10.3390/currenol29030154
9. "The Pattern of Second Primary Tumors in Postmenopausal Women with Prior Breast Cancer in Western Romania: A Retrospective, Single-Institution Study", *Diagnostics*,2021,11,1957. October.22. 2021, DOI:10.3390/diagnostics11111957
10. "Well-Being, Depression, and Anxiety following Oncoplastic Breast Conserving Surgery versus Modified Radical Mastectomy Followed by Late Breast Reconstruction". *International Journal of Environmental Research and Public Health* 18(17):9320. September.2021. DOI: 10.3390/ijerph18179320
11. "Carcinomatous-like mastitis due to axillary lymphadenopathy in a case of nasopharyngeal carcinoma: A case report". *Experimental and Therapeutic. Medicine*. July.2021. DOI: 10.3892/etm.2021.10458

12. **“Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1–Selected Non-Small Cell Lung Cancer”**. *Journal of Thoracic Oncology*. July. 12. 2021. DOI: [10.1016/j.jtho.2021.06.019](https://doi.org/10.1016/j.jtho.2021.06.019)
13. **“Comparative hematological profiles for dose-dense vs. regular anthracycline-based neoadjuvant chemotherapy in non-metastatic breast cancer”** *Experimental ,and Therapeutic. Medicine*. 11.May.2021. DOI: [10.3892/etm.2021.10179](https://doi.org/10.3892/etm.2021.10179)
14. **“Unilateral Orbital Metastasis as the Unique Symptom in the Onset of Breast Cancer in a Postmenopausal Woman: Case Report and Review of the Literature”** *Diagnostics* 2021,11, 725. April. 19.2021. Doi.org/[10.3390.diagnostics11040725/](https://doi.org/10.3390.diagnostics11040725/)
15. **“Skin-Reducing Mastectomy and Immediate Reconstruction for a Large Recurrent Borderline Phyllodes Tumor”**, *Applied Science*.29.January 2021, 11, 1224. Doi./[10.3390/app11031224](https://doi.org/10.3390/app11031224)
16. **“Endurance of erythrocyte series in chemotherapy”** *Experimental&Therapeutic.Medicine*.2020December.20(6):214. DOI:[10.3892/etm.2020.9344](https://doi.org/10.3892/etm.2020.9344)
17. **“Postmenopausal Breast Cancer in Women, Clinical and Epidemiological Factors Related to the Molecular Subtype: A Retrospective Cohort Study in a Single Institution for 13 Years. Follow-Up Data”**, *International Journal of Environmental Research and PublicHealth*.November24.2020.17(23),8722,DOI[10.3390/ijerph17238722](https://doi.org/10.3390/ijerph17238722)
18. **“Determining factors of renal dysfunction during cisplatin chemotherapy”**. *Experimental ,and Therapeutic. Medicine* November. 26.2020. DOI:[10.3892/ETM.2020.9516](https://doi.org/10.3892/ETM.2020.9516)
19. **“Veliparib with carboplatin and paclitaxel in BRCA mutated advanced breast cancer( BROCADE3): a randomized, double-blind, placebo-controlled, phase 3 trial”**,*The Lancet Oncology*.2020 Oct;21 (10):1269-1282. Doi: [10.1016/S1470-2045\(20\)30447-2](https://doi.org/10.1016/S1470-2045(20)30447-2). Epub 2020. Aug27
20. **“Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab vs chemotherapy in 1L metastatic NSCLC”**. *Journal of Clinical Oncology*.38(15 suppl):9594-9594. May2020, DOI:[10.1200/JCO.2020.38.15\\_suppl.9594](https://doi.org/10.1200/JCO.2020.38.15_suppl.9594)
21. **“The influence of cognitive schemas on mixed anxiety-depressive symptoms of breast of breast cancer patients”**. *BMC Womens Health*. 2020. Feb. 24; 20(1):32 . doi.[10.1186/s12905-020-00898-7](https://doi.org/10.1186/s12905-020-00898-7)
22. **“LBA9Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer”**. *Annals of Oncology* 30 (Supplement 5).October.2019. DOI: [10.1093/annonc/mdz394.008](https://doi.org/10.1093/annonc/mdz394.008)
23. **“Efficacy and safety of CetuGEX in reoccurrence/metastatic squamous cell carcinoma of head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study”**. *Journal of Clinical Oncology* 36.nr 5 suppl. February 10,2018, 59-59
24. **Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients”**. *European journal of cancer (Oxford, England:1990)* 82.June.2017. DOI: [10.1016/j.ejca.2017.05.010](https://doi.org/10.1016/j.ejca.2017.05.010)
25. **“Effectiveness and safety profile of ipilimumab therapy in previously treated patients with unrespectable or metastatic melanoma-the Romanian Patient Access Program“**. *J BUON*. Vol 23. Issue5.2017Sep-Oct;1287-1295

26. **“NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron”**, Supportive Cancer Care. Nov. 26. 2016
27. **“Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study )”**, Frontiers in Oncology. Article 232. Volume 6. October. 31. 2016
28. **“The benefit of Fasodex administration in metastatic breast cancer”-case presentation** “Oncologia AZI”-nr5/November 2014pg4
29. **“Randomized phase II study of MEHD 7945A(MEHD)vs Cetuximab(CET) in >1 line recurrent/metastatic squamous cell carcinoma of the head & neck progressive on/after platinum based chemotherapy”Abstract 9860** -Annals of Oncology Volume 25, Supplement 4, September 2014
30. **“A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy”**; Annals of Oncology vol 25, Nr7. July 2014 ISSN 1328-1333
31. **“No evidence of increased cyclophosphamide toxicity associated with the antiemetic agent NEPA, a fixed dose combination of Netupitant and Palonosetron** “ poster presentation abstract 2949- 55<sup>th</sup> ASH Annual Meeting New Orleans. December 2013
32. **“DORINTA-the support group for breast cancer patients”** –poster presentation 2012 International MASCC Symposium NY June 2012 abstract 156 ; Supportive cancer care 2012 Nr 20 Suppl1 pg S44
33. **“Principles of Medical Oncology** “- chapter in book “General Oncology” .2011. Victor Babes Editure Timisoara. Romania
34. **“CELER: an international randomized phase III trial of the CESAR Group: should chemotherapy be added to hormonal therapy in advanced breast cancer?”**; The Breast vol 16(Supp 1). March 2007
35. **“The Impact of Psychological Interventions on Breast Cancer Patients. A Romanian Pilot Study”**; Psycho-Oncology 15 (Supp.2), Oct. 2006, S422-423, ISSN 1057-9249
36. **“Results of a patient information campaign using a printed material”**- abstract- Annals of Oncology volume 17, 2006, Supplement 9, pg ix281
37. **“Oncomed- an oncology unit in Romania”**-poster presentation. Improving Cancer Services Conference. March. 2005. Milano. Italy
38. **“Lung cancer in elderly”**-chapter in book” Lung diseases in elderly”. 2004.
39. **“Clinical Oncology”**-chapter in book “Psycho-Oncology” 2003. Mirton. Editure. Timisoara. Romania
40. **“The results of psychotherapeutic interventions on patients with cancer disease”**- oral presentation. National Romanian Psychiatry Conference. October. 2002. Timisoara. Romania
41. **“Management of febrile Neutrogena after chemotherapy”**- database. National Oncology Conference. November .2001. Bucharest. Romania
42. **“Achantosis Nigricans – para-neoplastic syndrome at a patient with non-small lung cancer”** -case presentation. Romanian Society of Radiotherapy Conference. October. 2001. Oradea. Romania

**Awards received**

- 2010-May. 01-31 **EUSOMA-ESO-ESSO-Grant for Training Project** –visiting doctor in a Breast Cancer Unit-Frauenkliniken der Ludwig-Maximilians University. Munich
- 2009. May. **Susan G Kommen for the Cure Travel Grant** for participation at

first IMPAKT Breast Cancer Conference held in Brussels. Belgium  
 -2008.June- **MASCC.Travel Scholarship** for participation at MASCC/ISO International Symposium Supportive Care in Cancer. Houston. Texas  
 -2007.March- "**CELER Award 2006** – the top recruiter of this year"- Central European Society for Anticancer Drug Research. St.Gallen. Schweiz  
 -2005.April- **ESMO TRU Visit Grant**. Vall d'Hebron Hospital. Barcelona  
 -2004- **I Prize** Liberate's quiz competition Investig. Meeting.Antalya. Turkey  
 -2003-**II.Prize** quiz competition Cell-Therapeutics Investig. Meeting.Lisbon.  
 -1997.January - **SOROS scholarship** for Timis county for participation at "Emergency Medicine Course", held in Targu Mures. Romania

**Professional membership**

-Romanian Society of Medical Oncology - since December 1999  
 -European Society of Clinical Oncology(ESMO) – since September 2002  
 - Multinational Association of Supportive Care in Cancer(MASCC)since 2007  
 - European Association for Cancer Research(EACR)-since 2008

**Languages**

-ENGLISH	-Read/	Write/	Speak:	Fluent/	Fluent/	Fluent
-FRENCH	-Read/	Write/	Speak:	Good/	Good/	Some
-GERMAN	- Read/	Write/	Speak:	Good/	Good/	Good

Dr Cristina Oprean . 05.June.2025